Nexus Resultados de beneficios anteriores

Pasado controles de criterios 5/6

Nexus ha aumentado sus beneficios a una tasa media anual de 17.9%, mientras que los beneficios de la industria de Healthcare Services han experimentado un crecimiento de 2.2% anual. Los ingresos han ido creciendo a una tasa media de 11.1% al año. La rentabilidad financiera de Nexus es de 9.2%, y sus márgenes netos son de 9.8%.

Información clave

17.9%

Tasa de crecimiento de los beneficios

16.4%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services 7.9%
Tasa de crecimiento de los ingresos11.1%
Rentabilidad financiera9.2%
Margen neto9.8%
Próxima actualización de resultados14 May 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Should You Investigate Nexus AG (ETR:NXU) At €52.80?

Apr 20
Should You Investigate Nexus AG (ETR:NXU) At €52.80?

Nexus AG (ETR:NXU) Shares Could Be 27% Below Their Intrinsic Value Estimate

Mar 28
Nexus AG (ETR:NXU) Shares Could Be 27% Below Their Intrinsic Value Estimate

Earnings Update: Nexus AG (ETR:NXU) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Mar 08
Earnings Update: Nexus AG (ETR:NXU) Just Reported Its Full-Year Results And Analysts Are Updating Their Forecasts

Returns On Capital At Nexus (ETR:NXU) Have Stalled

Feb 10
Returns On Capital At Nexus (ETR:NXU) Have Stalled

Why Nexus AG (ETR:NXU) Could Be Worth Watching

Jan 16
Why Nexus AG (ETR:NXU) Could Be Worth Watching

Is There An Opportunity With Nexus AG's (ETR:NXU) 23% Undervaluation?

Nov 06
Is There An Opportunity With Nexus AG's (ETR:NXU) 23% Undervaluation?

Returns On Capital At Nexus (ETR:NXU) Have Stalled

Apr 22
Returns On Capital At Nexus (ETR:NXU) Have Stalled

Is Nexus AG (ETR:NXU) Potentially Undervalued?

Apr 01
Is Nexus AG (ETR:NXU) Potentially Undervalued?

Here's What To Make Of Nexus' (ETR:NXU) Decelerating Rates Of Return

Jan 06
Here's What To Make Of Nexus' (ETR:NXU) Decelerating Rates Of Return

Should You Think About Buying Nexus AG (ETR:NXU) Now?

Nov 10
Should You Think About Buying Nexus AG (ETR:NXU) Now?

Nexus (ETR:NXU) Is Looking To Continue Growing Its Returns On Capital

Jun 25
Nexus (ETR:NXU) Is Looking To Continue Growing Its Returns On Capital

Should You Think About Buying Nexus AG (ETR:NXU) Now?

Apr 23
Should You Think About Buying Nexus AG (ETR:NXU) Now?

Nexus (ETR:NXU) Has More To Do To Multiply In Value Going Forward

Feb 23
Nexus (ETR:NXU) Has More To Do To Multiply In Value Going Forward

Estimating The Intrinsic Value Of Nexus AG (ETR:NXU)

Jul 30
Estimating The Intrinsic Value Of Nexus AG (ETR:NXU)

Returns On Capital At Nexus (ETR:NXU) Have Hit The Brakes

Jun 29
Returns On Capital At Nexus (ETR:NXU) Have Hit The Brakes

Estimating The Intrinsic Value Of Nexus AG (ETR:NXU)

Apr 19
Estimating The Intrinsic Value Of Nexus AG (ETR:NXU)

Nexus (ETR:NXU) Hasn't Managed To Accelerate Its Returns

Mar 30
Nexus (ETR:NXU) Hasn't Managed To Accelerate Its Returns

Shareholders Are Thrilled That The Nexus (ETR:NXU) Share Price Increased 209%

Mar 11
Shareholders Are Thrilled That The Nexus (ETR:NXU) Share Price Increased 209%

Do Institutions Own Nexus AG (ETR:NXU) Shares?

Feb 22
Do Institutions Own Nexus AG (ETR:NXU) Shares?

Nexus AG's (ETR:NXU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04
Nexus AG's (ETR:NXU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Calculating The Intrinsic Value Of Nexus AG (ETR:NXU)

Jan 18
Calculating The Intrinsic Value Of Nexus AG (ETR:NXU)

We're Watching These Trends At Nexus (ETR:NXU)

Dec 29
We're Watching These Trends At Nexus (ETR:NXU)

Introducing Nexus (ETR:NXU), The Stock That Zoomed 189% In The Last Five Years

Nov 30
Introducing Nexus (ETR:NXU), The Stock That Zoomed 189% In The Last Five Years

Is Nexus AG's (ETR:NXU) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Jun 30
Is Nexus AG's (ETR:NXU) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Nexus. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

XTRA:NXU Ingresos, gastos y beneficios (EUR Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 232452400
30 Sep 232332400
30 Jun 232242100
31 Mar 232172100
31 Dec 222121900
30 Sep 222042000
30 Jun 222001900
31 Mar 221961800
31 Dec 211911700
30 Sep 211881700
30 Jun 211791600
31 Mar 211711600
31 Dec 201661500
30 Sep 201601300
30 Jun 201591300
31 Mar 201551100
31 Dec 191511100
30 Sep 191511000
30 Jun 191451000
31 Mar 191441100
31 Dec 181411100
30 Sep 181331100
30 Jun 181301000
31 Mar 181271000
31 Dec 171241000
30 Sep 17121900
30 Jun 17119900
31 Mar 17115800
31 Dec 16112800
30 Sep 16110800
30 Jun 16108700
31 Mar 16106800
31 Dec 15103800
30 Sep 1599900
30 Jun 1594900
31 Mar 1589800
31 Dec 1485800
30 Sep 1482700
30 Jun 1481800
31 Mar 1480700
31 Dec 1378700
30 Sep 1375700
30 Jun 1372700

Ingresos de calidad: NXU tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (9.8%) de NXU son superiores a los del año pasado (9.1%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de NXU han crecido un 17.9% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de NXU en el último año (24.2%) supera su media de 5 años (17.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de NXU en el último año (24.2%) superó al de la industria Healthcare Services -36.8%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de NXU (9.2%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target